Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time

Rhea-AI Summary

Senseonics Holdings, Inc. (NYSE American: SENS) has announced it will release its third quarter 2022 financial results after market close on November 8, 2022. The management will host a conference call at 4:30 p.m. ET on the same day to discuss the company's performance. Senseonics focuses on long-term, implantable continuous glucose monitoring (CGM) systems aimed at the diabetes community, with products like Eversense® and Eversense® XL providing real-time glucose data through a small sensor under the skin.

Positive

• Scheduled release of third quarter 2022 financial results, indicating ongoing communication with investors.

Negative

• None.

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022.

Management will hold a conference call to review the Company’s third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 1126379, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005947/en/

Senseonics Investor Contact

Philip Taylor

Investor Relations

415-937-5406

investors@senseonics.com

Source: Senseonics Holdings, Inc.

FAQ

When will Senseonics release its third quarter 2022 financial results?

Senseonics will release its third quarter 2022 financial results on November 8, 2022.

What time is the conference call for Senseonics' financial results?

The conference call will take place at 4:30 p.m. Eastern Time on November 8, 2022.

How can I access the Senseonics conference call?

You can access the conference call by dialing 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International) and using the passcode 1126379.

What technology does Senseonics develop for diabetes management?

Senseonics develops long-term, implantable continuous glucose monitoring systems, including Eversense® and Eversense® XL.